Literature DB >> 24314868

Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea.

Piwen Wang1, Jaydutt V Vadgama, Jonathan W Said, Clara E Magyar, Ngan Doan, David Heber, Susanne M Henning.   

Abstract

The chemopreventive activity of green tea (GT) is limited by the low bioavailability and extensive methylation of GT polyphenols (GTPs) in vivo. We determined whether a methylation inhibitor quercetin (Q) will enhance the chemoprevention of prostate cancer in vivo. Androgen-sensitive LAPC-4 prostate cancer cells were injected subcutaneously into severe combined immunodeficiency (SCID) mice one week before the intervention. The concentration of GTPs in brewed tea administered as drinking water was 0.07% and Q was supplemented in diet at 0.2% or 0.4%. After 6-weeks of intervention tumor growth was inhibited by 3% (0.2% Q), 15% (0.4% Q), 21% (GT), 28% (GT+0.2% Q) and 45% (GT+0.4% Q) compared to control. The concentration of non-methylated GTPs was significantly increased in tumor tissue with GT+0.4% Q treatment compared to GT alone, and was associated with a decreased protein expression of catechol-O-methyltransferase and multidrug resistance-associated protein (MRP)-1. The combination treatment was also associated with a significant increase in the inhibition of proliferation, androgen receptor and phosphatidylinositol 3-kinase/Akt signaling, and stimulation of apoptosis. The combined effect of GT+0.4% Q on tumor inhibition was further confirmed in another experiment where the intervention started prior to tumor inoculation. These results provide a novel regimen by combining GT and Q to improve chemoprevention in a non-toxic manner and warrant future studies in humans.
© 2014.

Entities:  

Keywords:  4″-MeEGCG; 4″-O-methyl EGCG; AR; COMT; Catechol-O-methyltransferase; EC, (−)-epicatechin; ECG, (−)-epicatechin-3-gallate; EGC; EGCG, (−); GT; GTPs; Green tea; HD; HPLC; LD; MRP; PI3K; PSA; Prostate cancer; Q; Quercetin; SCID; SCID mice; androgen receptor; catechol-O-methyltransferase; epigallocatechin; epigallocatechin-3-gallate; green tea; green tea polyphenols; high dose; high-performance liquid chromatography; low dose; mTOR; mammalian target of rapamycin; multidrug resistance-associated protein; phosphatidylinositol 3-kinases; prostate-specific antigen; quercetin; severe combined immunodeficiency

Mesh:

Substances:

Year:  2013        PMID: 24314868      PMCID: PMC3858726          DOI: 10.1016/j.jnutbio.2013.09.005

Source DB:  PubMed          Journal:  J Nutr Biochem        ISSN: 0955-2863            Impact factor:   6.048


  43 in total

1.  Genetic Association Between the COMT Genotype and Urinary Levels of Tea Polyphenols and Their Metabolites among Daily Green Tea Drinkers.

Authors:  Maki Inoue-Choi; Jian-Min Yuan; Chung S Yang; David J Van Den Berg; Mao-Jung Lee; Yu-Tang Gao; Mimi C Yu
Journal:  Int J Mol Epidemiol Genet       Date:  2010

2.  Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer.

Authors:  Imtiaz A Siddiqui; Mohammad Asim; Bilal B Hafeez; Vaqar M Adhami; Rohinton S Tarapore; Hasan Mukhtar
Journal:  FASEB J       Date:  2010-12-21       Impact factor: 5.191

3.  Quercetin increased the antiproliferative activity of green tea polyphenol (-)-epigallocatechin gallate in prostate cancer cells.

Authors:  Piwen Wang; David Heber; Susanne M Henning
Journal:  Nutr Cancer       Date:  2012-03-27       Impact factor: 2.900

4.  Human metabolism of dietary flavonoids: identification of plasma metabolites of quercetin.

Authors:  A J Day; F Mellon; D Barron; G Sarrazin; M R Morgan; G Williamson
Journal:  Free Radic Res       Date:  2001-12

5.  Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study.

Authors:  Saverio Bettuzzi; Maurizio Brausi; Federica Rizzi; Giovanni Castagnetti; Giancarlo Peracchia; Arnaldo Corti
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

6.  Dose-response to 3 months of quercetin-containing supplements on metabolite and quercetin conjugate profile in adults.

Authors:  Lynn Cialdella-Kam; David C Nieman; Wei Sha; Mary Pat Meaney; Amy M Knab; R Andrew Shanely
Journal:  Br J Nutr       Date:  2012-11-14       Impact factor: 3.718

Review 7.  Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.

Authors:  Todd M Morgan; Theodore D Koreckij; Eva Corey
Journal:  Curr Cancer Drug Targets       Date:  2009-03       Impact factor: 3.428

Review 8.  miRNA as molecular target of polyphenols underlying their biological effects.

Authors:  Dragan Milenkovic; Baptiste Jude; Christine Morand
Journal:  Free Radic Biol Med       Date:  2013-06-07       Impact factor: 7.376

9.  Nongallated compared with gallated flavan-3-ols in green and black tea are more bioavailable.

Authors:  Susanne M Henning; Jung J Choo; David Heber
Journal:  J Nutr       Date:  2008-08       Impact factor: 4.798

10.  Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses.

Authors:  J Blancato; B Singh; A Liu; D J Liao; R B Dickson
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

View more
  24 in total

1.  Risk of prostate cancer in African-American men: Evidence of mixed effects of dietary quercetin by serum vitamin D status.

Authors:  C J Paller; Y M Kanaan; D A Beyene; T J Naab; R L Copeland; H L Tsai; N F Kanarek; T S Hudson
Journal:  Prostate       Date:  2015-06-05       Impact factor: 4.104

2.  Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy.

Authors:  Susanne M Henning; Piwen Wang; Jonathan W Said; Min Huang; Tristan Grogan; David Elashoff; Catherine L Carpenter; David Heber; William J Aronson
Journal:  Prostate       Date:  2014-12-24       Impact factor: 4.104

3.  Systems pharmacogenomics - gene, disease, drug and placebo interactions: a case study in COMT.

Authors:  Kathryn T Hall; Joseph Loscalzo; Ted J Kaptchuk
Journal:  Pharmacogenomics       Date:  2019-05       Impact factor: 2.533

4.  Prospective randomized trial evaluating blood and prostate tissue concentrations of green tea polyphenols and quercetin in men with prostate cancer.

Authors:  Susanne M Henning; Piwen Wang; Ru-Po Lee; Amy Trang; George Husari; Jieping Yang; Emma M Grojean; Austin Ly; Mark Hsu; David Heber; Tristan Grogan; Zhaoping Li; William J Aronson
Journal:  Food Funct       Date:  2020-04-29       Impact factor: 5.396

5.  Arctigenin in combination with quercetin synergistically enhances the antiproliferative effect in prostate cancer cells.

Authors:  Piwen Wang; Tien Phan; David Gordon; Seyung Chung; Susanne M Henning; Jaydutt V Vadgama
Journal:  Mol Nutr Food Res       Date:  2014-12-05       Impact factor: 5.914

Review 6.  Epigenetics in breast and prostate cancer.

Authors:  Yanyuan Wu; Marianna Sarkissyan; Jaydutt V Vadgama
Journal:  Methods Mol Biol       Date:  2015

7.  Nitrogen-containing derivatives of O-tetramethylquercetin: Synthesis and biological profiles in prostate cancer cell models.

Authors:  Pravien Rajaram; Ziran Jiang; Guanglin Chen; Alyssa Rivera; Alison Phasakda; Qiang Zhang; Shilong Zheng; Guangdi Wang; Qiao-Hong Chen
Journal:  Bioorg Chem       Date:  2019-03-19       Impact factor: 5.275

8.  Sensitization to docetaxel in prostate cancer cells by green tea and quercetin.

Authors:  Piwen Wang; Susanne M Henning; David Heber; Jaydutt V Vadgama
Journal:  J Nutr Biochem       Date:  2015-01-15       Impact factor: 6.048

9.  Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells.

Authors:  Piwen Wang; Bin Wang; Seyung Chung; Yanyuan Wu; Susanne M Henning; Jaydutt V Vadgama
Journal:  RSC Adv       Date:  2014-08-05       Impact factor: 3.361

Review 10.  Natural Products That Target Cancer Stem Cells.

Authors:  Jim Moselhy; Sowmyalakshmi Srinivasan; Murali K Ankem; Chendil Damodaran
Journal:  Anticancer Res       Date:  2015-11       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.